Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Medtronic (NY:MDT)

94.27 -1.14 (-1.19%)
Delayed Quote Updated: 1:04 PM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Medtronic

< Previous 1 2 3 4 5 6 7 8 9
...
69 70 Next >
News headline image
3 Healthcare Stocks That Pay You a Dividend While You Wait for a Recovery ↗
As you wait for stock prices to rebound, these three healthcare companies pay dividends with generous yields. 
Via The Motley Fool
Topics Intellectual Property World Trade
News headline image
What You Need to Know Ahead of Medtronic's Earnings Release
Medtronic is expected to release its fiscal fourth-quarter earnings soon, and analysts project a single-digit profit drop. 
Via Barchart.com
Topics ETFs
News headline image
Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Intuitive Surgical's Selloff Sets Up a 30% Rebound Opportunity ↗
Via MarketBeat
Medtronic PLC (NYSE:MDT): A Durable Dividend Stock for Income Investors ↗
Via Chartmill
News headline image
Stock Market Today, April 22: Boston Scientific Jumps After Q1 Earnings Beat Resets Growth Expectations ↗
On April 22, 2026, investors weigh a rare combo of earnings strength and softer long-term targets reshaping this medtech leader’s outlook. 
Via The Motley Fool
Topics Earnings Stocks
News headline image
Could This Healthcare Stock Help Make You Rich Over the Next Decade? ↗
Intuitive Surgical has already made many of its early investors wealthy. 
Via The Motley Fool
News headline image
3 Magnificent Dividend Stocks the Sell-Off Has Put on Sale. Buy Them Now and Hold Forever. ↗
With these Dividend Kings, the market's pain is your gain. 
Via The Motley Fool
News headline image
The Infrastructure Play Hiding in Plain Sight Across Cardiac Care
Issued on behalf of VentriPoint Diagnostics Ltd. 
From Equity Insider
Via GlobeNewswire
News headline image
Envoy Medical Appoints Chas McKhann to Board of Directors
White Bear Lake, Minnesota--(Newsfile Corp. - April 16, 2026) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company... 
Via Newsfile
News headline image
J&J Shatters Estimates as Oncology and MedTech Power 2026 Outlook Higher
Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Inflation Fever Breaks: March PPI Data Offers Unexpected Relief to Markets
The financial markets received a much-needed breath of fresh air this week as the Bureau of Labor Statistics released the Producer Price Index (PPI) report for March 2026. Final demand prices rose by... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Boston Scientific’s $14.9 Billion Bet: The Strategic "Homecoming" to Neurovascular Dominance
As of April 15, 2026, the medical technology landscape is bracing for its most significant transformation in years. Boston Scientific (NYSE:BSX) is moving steadily toward the finalization of its $14.9... 
Via MarketMinute
Topics Economy
News headline image
Consolidation Fever: Boston Scientific’s $14.9 Billion Bet on Penumbra Signals New Era in MedTech M&A
In a move that has sent shockwaves through the healthcare sector, Boston Scientific Corporation (NYSE: BSX) announced its definitive agreement to acquire Penumbra, Inc. (NYSE: PEN) for approximately... 
Via MarketMinute
Topics Economy
News headline image
MedTech Surge and Oncology Resilience Drive Johnson & Johnson to Q1 Earnings Beat
In a resounding display of corporate resilience, Johnson & Johnson (NYSE:JNJ) reported first-quarter 2026 financial results that surpassed Wall Street expectations, signaling a successful navigation of... 
Via MarketMinute
Topics Bankruptcy Earnings Economy
News headline image
Johnson & Johnson Shatters Expectations in Q1 2026, Raising Full-Year Outlook as Healthcare Giant Pushes Toward $100 Billion Milestone
NEW BRUNSWICK, N.J. — In a powerful display of resilience and strategic execution, Johnson & Johnson (NYSE: JNJ) reported first-quarter 2026 financial results that exceeded Wall Street estimates across... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
The New J&J: A 2026 Deep Dive into the Global Healthcare Titan
As of April 14, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different entity than it was only three years ago. Following the successful spin-off of its consumer health division, Kenvue,... 
Via Finterra
Topics Artificial Intelligence Death Economy
News headline image
The Teleflex Pivot: Inside the $1 Billion Share Buyback and Strategic Breakup
Disclaimer: This content is intended for informational purposes only and is not financial advice. Today’s date is April 9, 2026. Introduction In the high-stakes arena of medical technology, few stories... 
Via Finterra
Topics Economy World Trade
News headline image
Telix Strengthens Board with Additional Director Appointments
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
3 Dividend Stocks to Double Up On Right Now ↗
From energy to healthcare, this trio of reliable dividend payers are worth a deep dive today. 
Via The Motley Fool
Topics Economy
News headline image
This Healthcare Stock Has No Debt and a Near-Monopoly in Its Market ↗
The company is a picture of financial stability. 
Via The Motley Fool
News headline image
Hologic, Inc. (NASDAQ: HOLX): A New Chapter as a Women’s Health Powerhouse
Today marks a definitive turning point for Hologic, Inc. (NASDAQ: HOLX). As the company prepares to finalize its $18.3 billion acquisition by private equity giants Blackstone and TPG, it stands as a... 
Via Finterra
Topics Artificial Intelligence Retirement World Trade
News headline image
Robotic Revolution in the Electrophysiology Lab: FDA Clears Stereotaxis Synchrony System
ST. LOUIS – April 6, 2026 – In a milestone that signals a paradigm shift for cardiac care, Stereotaxis (NYSE American: STXS) has received FDA 510(k) clearance for its Synchrony™ System. The approval... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
Stereotaxis Secures FDA Clearance for Synchrony™ System, Completing Its Vision for the Robotic "Digital Cockpit"
ST. LOUIS — April 6, 2026 — Stereotaxis (NYSE: STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias and other endovascular procedures, announced today that... 
Via MarketMinute
News headline image
The “New BD”: A Deep-Dive Research Report on Becton, Dickinson and Company (BDX) in 2026
As of April 3, 2026, the medical technology landscape is undergoing a radical transformation, and few companies embody this evolution more than Becton, Dickinson and Company (NYSE: BDX). Known... 
Via Finterra
Topics Artificial Intelligence
News headline image
The Martha Transformation: A Deep Dive into Medtronic’s 2026 Pivot
As of April 3, 2026, Medtronic plc (NYSE: MDT) stands at a critical inflection point in its 77-year history. Once viewed as a lumbering healthcare conglomerate burdened by its own scale, the... 
Via Finterra
Topics Artificial Intelligence Initial Public Offering Product Recall
News headline image
Med-Tech Resilience: AngioDynamics Pivot Pays Off with Double-Digit Growth and Profitability
The medical technology sector has long been a bellwether for the health of the broader economy and the efficiency of the healthcare system. Today, April 2, 2026, AngioDynamics (NASDAQ:ANGO) provided... 
Via MarketMinute
Topics Economy Retirement
News headline image
The Medtronic Transformation: A Deep Dive into the Future of a MedTech Titan
As of April 1, 2026, the global medical technology landscape is undergoing a profound shift, and at the center of this evolution is Medtronic plc (NYSE: MDT). Long regarded as the "sleeping giant" of... 
Via Finterra
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
The New Blue-Chip: How Johnson & Johnson Refined Its Empire for a High-Growth Future
As we enter the second quarter of 2026, Johnson & Johnson (NYSE: JNJ) stands as a starkly different entity than the consumer-facing conglomerate that defined the 20th century. Having successfully shed... 
Via Finterra
Topics Artificial Intelligence Earnings Economy
News headline image
This Dividend King Is Down 26%. When Will It Bounce Back?
Abbott Laboratories is down 26% from its 52-week high due to a soft quarter. With 54 consecutive years of dividend hikes and guidance calling for mid-single-digit organic sales growth plus 10% EPS... 
Via Barchart.com
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
69 70 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.